Bioequivalence of topical clotrimazole formulations: An improved tape stripping method

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 3, 2011, Pages 347-357

  Parfitt, Natalie Rae ^a   Skinner, Michael ^a   Bon, Charles ^b   Kanfer, Isadore ^a  

^a RHODES UNIVERSITY   (South Africa)

^b Biostudy Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE;

ADULT; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG FORMULATION; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PHARMACEUTICS; SINGLE DRUG DOSE; SKIN PENETRATION; SKIN STRUCTURE; SKIN WATER LOSS; SKINFOLD THICKNESS; STRATUM CORNEUM; TAPE STRIPPING METHOD;

EID: 80052738615     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3rp5k     Document Type: Article

References (24)

1. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Topical Dermatological Corticosteroids: In vivo Bioequivalence. Rockville: Food and Drug Administration; 1995.
2. Herkenne C, Alberti I, Naik A, Kalia YN, Mathy F, Preat V, et al. In vivo methods for the assessment of topical drug bioavailability. Pharm Res, 25(1):87-103, 2008.
3. Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH. Dermatopharmacokinetic prediction of topical drug bioavailability in vivo. J Invest Dermatol, 127(4):887-894, 2007.
4. Herkenne C, Naik A, Kalia YN, Hadgraft J, Guy RH. Ibuprofen transport into and through skin from topical formulations: In vitro-in vivo comparison. J Invest Dermatol, 127(1):135-142, 2007.
5. Pershing LK, Corlett JL, Nelson JL. Comparison of dermatopharmacokinetic vs. clinical efficacy methods for bioequivalence assessment of miconazole nitrate vaginal cream, 2% in humans. Pharm Res, 19(3):270-277, 2002.
6. Pershing LK, Corlett J, Jorgensen C. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob Agents Chemother, 38(1):90-95, 1994.
7. Navidi W, Hutchinson A, N'Dri-Stempfer B, Bunge AL. Determining bioequivalence of topical dermatological drug products by tape-stripping. J Pharmacokinet Pharmacodyn, 35(3):337-348, 2008.
8. Benfeldt E, Hansen SH, Vølund A, Menne T, Shah VP. Bioequivalence of topical formulations in humans: Evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol, 127(1):170-178, 2007.
9. Lodén M, Akerström U, Lindahl K, Berne B. Bioequivalence determination of topical ketoprofen using a dermatopharmacokinetic approach and excised skin penetration. Int J Pharm, 284(1-2):23-30, 2004.
10. Lademann J, Jacobi U, Surber C, Weigmann H.-J., Fluhr J. The tape stripping procedure - evaluation of some critical parameters. Eur J Pharm Biopharm. 72(2):317-323, 2009.
11. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry Topical Dermatological Drug Product NDAs and ANDAs -In vivo Bioavailability, Bioequivalence, In vitro Release, and Associated Studies. Rockville: Food and Drug Administration; 1998.
12. Pershing LK, Nelson JL, Corlett JL, Shrivastava SP, Hare DB, Shah VP. Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol, 48(5):740-751, 2002.
13. Food and Drug Administration, HHS. Dermatological Drug Product NDAs and ANDAs-In Vivo Bioavailability, Bioequivalence, In Vitro Release and Associated Studies; Withdrawal. Federal Register. 17 May 2002;67(96):35122-35123.
14. N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res, 26(2):316-328, 2009.
15. N'Dri-Stempfer B, Navidi W, Guy RH, Bunge AL. Optimising metrics for the assessment of bioequivalence between topical drug Products. Pharm Res, 25(7):1621-1630, 2008.
16. Kalia YN, Alberti I, Nabila S, Curdy C, Naik A, Guy RH. Normalization of stratum corneum barrier function and transepidermal water loss. Pharm Res, 17(9):1148-1150, 2000.
17. World Medical Association. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed 03/19, 2009.
18. Au WL, Skinner MF, Kanfer I. Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations. J Pharm PharmSci, 13(1):11-20, 2010.
19. Chow S-C, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinetic Pharmacodynam, 28(2):155-169, 2001.
20. Schuirmann DJ. A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm, 15(6):657-680, 1987.
21. Bolton, S.; Bon, C., Pharmaceutical Statistics: Practical and Clinical Applications. 5th ed, Taylor and Francis, USA, 2009.
22. Reddy MB, Stinchcomb AL, Guy RH, Bunge AL. Determining dermal absorption parameters in vivo from tape strip data. Pharm Res, 19(3):292-298, 2002.
23. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally AdministeredDrug Products - General Considerations. Rockville: Food and Drug Administration; 2003.
24. Niazi SK. Handbook of Bioequivalence Testing. USA: Informa Healthcare Inc; 2007. Drugs and the Pharmaceutical Sciences, Vol 171.